Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EKF Diagnostics HoldingsLSE:EKF +1.60%45 EV-to-EBITDA is 7.73 as of Aug. 28, 2026, which is 33% below its 10-year median of 11.57. GuruFocus rates LSE:EKF with a GF Score™ of 45/100 and a GF Value™ of £0.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 523 Medical Devices & Instruments companies, EKF Diagnostics Holdings ranks better than 75.33% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EKF Diagnostics Holdings's enterprise value is £97.74 Mil.
EKF Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £12.64 Mil. Therefore, EKF Diagnostics Holdings's EV-to-EBITDA for today is 7.73.
The historical rank and industry rank for EKF Diagnostics Holdings's EV-to-EBITDA or its related term are showing as below:
LSE:EKF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -97.6 Med: 11.57 Max: 34.15
Current: 7.73
During the past 13 years, the highest EV-to-EBITDA of EKF Diagnostics Holdings was 34.15. The lowest was -97.60. And the median was 11.57.
LSE:EKF's EV-to-EBITDA is ranked better than 75.33% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs LSE:EKF: 7.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EKF Diagnostics Holdings's PE Ratio (TTM) for today is calculated as:
EKF Diagnostics Holdings's share price for today is £0.253.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EKF Diagnostics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, EKF Diagnostics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EKF Diagnostics Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EKF Diagnostics Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EKF Diagnostics Holdings's EV-to-EBITDA falls into.
EKF Diagnostics Holdings's current Enterprise Value is £97.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EKF Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £12.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKF Diagnostics Holdings (LSE:EKF) has a EV-to-EBITDA of 7.73 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EKF Diagnostics Holdings. This is 33% below median its historical median of 11.57. According to the industry distribution chart, EKF Diagnostics Holdings ranks #129 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is EKF Diagnostics Holdings' EV-to-EBITDA too high?
EKF Diagnostics Holdings' current EV-to-EBITDA of 7.73 is 33% below median its 10-year median of 11.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.62. EKF Diagnostics Holdings' value of 7.73 is 47.1% below this industry median. Based on the distribution chart, EKF Diagnostics Holdings ranks #129 out of 523 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, EKF Diagnostics Holdings has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EKF Diagnostics Holdings' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EKF Diagnostics Holdings ranks #129 out of 523 companies for EV-to-EBITDA. This places EKF Diagnostics Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.62. EKF Diagnostics Holdings' value of 7.73 is 47.1% below this benchmark. While the company's 10-year median is 11.57 vs. the industry median of 14.62, EKF Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EKF Diagnostics Holdings's current EV-to-EBITDA of 7.73 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EKF Diagnostics Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EKF Diagnostics Holdings's current EV-to-EBITDA is 7.73, which is 33% below median its own 10-year median of 11.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EKF Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, EKF Diagnostics Holdings (LSE:EKF) is currently considered Fairly Valued. The stock's GF Value™ is £0.28, compared to a current price of £0.25 — trading 9.6% below its estimated fair value. The current EV-to-EBITDA is 7.73, which is 33% below median its 10-year median of 11.57 and 47.1% below the Medical Devices & Instruments industry median of 14.62. EKF Diagnostics Holdings' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For EKF Diagnostics Holdings (LSE:EKF), the current EV-to-EBITDA is 7.73 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EKF Diagnostics Holdings (LSE:EKF) Overvalued in 2026?
Based on GuruFocus' analysis, EKF Diagnostics Holdings stock appears to be undervalued.
The current stock price of £0.25 is trading 9.6% below its estimated GF Value™ of £0.28.
GuruFocus considers EKF Diagnostics Holdings to be Fairly Valued.
Key valuation signals for LSE:EKF:
EV-to-EBITDA: 7.73 (33% below median its 10-year median of 11.57)
GF Value™: £0.28 vs. price of £0.25 (9.6% below fair value)
Industry Position: 47.1% below the Medical Devices & Instruments median (#129 of 523)
No single metric tells the full story. See the LSE:EKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
45GF Score
Get the complete analysis for LSE:EKF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:EKF has been successfully added to your 
